Metamark Genetics is a biotechnology company based in the United States, founded in 2007. The company is dedicated to improving cancer care through advanced diagnostic and prognostic testing. Metamark, established by leading experts in cancer biology and personalized medicine, has emerged as a frontrunner in clinical proteomics, focusing on the study of protein signatures within healthy and diseased cells. Their expertise lies in the diagnosis and management of prostate cancer, bladder cancer, and other urologic conditions.
In November 2012, Metamark secured a significant $13.00M Series B investment, indicative of investor confidence in its innovative approach to cancer care. Notable investors who participated in this funding round are not specified.
As a pioneering force in cancer diagnostics and personalized medicine, Metamark Genetics continues to make significant strides in the field, positioning itself as a key player in advancing the management of various forms of cancer and urologic conditions.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Series B | $13.00M | - | 05 Nov 2012 | |
| Series B | $22.00M | 1 | Perseus | 13 Aug 2010 |
| Venture Round | $2.65M | - | 06 May 2009 |
No recent news or press coverage available for Metamark Genetics.
We care about your data, and we'd love to use cookies make your experience better.
